Login to Your Account



Washington Roundup

Naming of Biosimilars Is Becoming a Thorny Issue

By Mari Serebrov
Washington Editor

Thursday, June 7, 2012
WASHINGTON – Whether a biosimilar by any other name would be prescribed as readily as the brand biologic it mimics is the budding debate as the FDA moves forward on the biosimilar pathway.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription